Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SAGE3P is the sarcoma antigen 3, pseudogene, a genomic element annotated as a pseudogene and presumed to be a non-coding RNA locus. Pseudogenes are gene-like DNA sequences that typically do not encode functional proteins due to accumulated disabling mutations[3]. While some pseudogenes may exert regulatory functions—such as sequestering microRNAs or modulating parental gene expression—SAGE3P is not recognized in key genomic resources as a protein, receptor, enzyme, or validated drug target. There is no documented evidence linking SAGE3P to well-characterized molecular pathways, disease associations, or therapeutic functions, and it is not included in lists of actionable or diagnostically relevant pseudogenes. Its name suggests a relationship to cancer antigens, but this is not supported by functional or clinical data. The use of SAGE3P as a therapeutic target would be considered incorrect under current scientific understanding[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sarcoma antigen 3, pseudogene (SAGE3P).